Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Mancuso, Roberta ^a   Hernis, Ambra ^a   Agostini, Simone ^a   Rovaris, Marco ^a   Caputo, Domenico ^a   Fuchs, Dietmar ^b   Clerici, Mario ^a,c  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INDOLEAMINE 2,3 DIOXYGENASE; NEOPTERIN;

ADULT; ARTICLE; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; ENZYME ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IDO GENE; IFN GAMMA GENE; KYNURENINE TRYPTOPHAN RATIO; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REMISSION; UPREGULATION; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED;

ADULT; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPTERIN;

EID: 84938400978     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130715     Document Type: Article

References (36)

1. Stinissen P, Hellings N. Activation of myelin reactive T cells in multiple sclerosis: a possible role for T cell degeneracy? Eur J Immunol. 2008; 38:1190-1193. doi: 10.1002/eji.200838371 PMID: 18425726
2. Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014; 8:12. doi: 10.3389/fnins.2014.00012 PMID: 24567701
3. Munn DH, Mellor AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013; 34: 137-143. doi: 10.1016/j.it.2012.10.001 PMID: 23103127
4. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenineandthearyl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010; 185: 3190-3198. doi: 10.4049/jimmunol.0903670 PMID: 20720200
5. Liu XQ, Wang X. Indoleamine 2, 3-dioxygenase in tumor induced tolerance. Chin Med J (Engl). 2009; 122: 3072-3077. PMID: 20137504
6. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM. HIV-inducedtype I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One. 2008; 3: e2961. doi: 10.1371/journal.pone.0002961 PMID: 18698365
7. Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J Immunol. 2009; 183: 6303-6312. doi: 10.4049/jimmunol.0901577 PMID: 19841163
8. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13: 465-477. doi: 10.1038/nrn3257 PMID: 22678511
9. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 1991; 5: 2516-2522. PMID: 1907934
10. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem. 1996; 66: 996-1004. PMID: 8769859
11. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1996; 320: 595-597. PMID: 8973572
12. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002; 129:186-196. PMID: 12161035
13. Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005; 19:1347-1349. PMID: 15939737
14. Monaco F, Fumero S, Mondino A, Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J Neurol Neurosurg Psychiatry. 1979; 42: 640-641. PMID: 479903
15. Fuchs D, Reibnegger G, Werner ER, Wachter H. Immune-mediated mechanisms in multiple sclerosis. J Neurol. 1990; 237:125. PMID: 2355238
16. Rudzite V, Berzinsh J, Grivane I, Fuchs D, Baier-Bitterlich G, Wachter H. Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS). Adv Exp Med Biol. 1996; 398:183-187. PMID: 8906264
17. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69: 292-302. doi: 10.1002/ana.22366 PMID: 21387374
18. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNAquantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett. 2006; 28: 1601-1613. PMID: 16900335
19. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997; 43: 2424-2426. PMID: 9439467
20. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30: e36. PMID: 11972351
21. Macchiarulo A, Camaioni E, Nuti R, Pellicciari R. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2, 3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids. 2009; 37: 219-229. doi: 10.1007/s00726-008-0137-3 PMID: 18612775
22. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, Wada H, Noma A, Seishima M. Lipopoly-saccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-inde-pendent mechanism. Eur J Immunol. 2001; 31: 2318-2318.
23. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002; 3:175-187. PMID: 12003349
24. Kahl KG, Kruse N, Toyka KV, Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. Neurol Sci. 2002; 200: 53-55. PMID: 12127676
25. Ferrante P, Fusi ML, Saresella M, Caputo D, Biasin M, Trabattoni D et al. Cytokine production and surface markers expression in acute and stable multiple sclerosis. Dysregulated IL-12 production and augmented SLAM-expressing lymphocytes in acute multiple sclerosis. J Immunol. 1998; 160:1514-1521. PMID: 9570575
26. Clerici M, Saresella M, Trabattoni D, Speciale L, Fossati S, Ruzante S, et al. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J Neuroimmunol. 2001; 121: 88-101. PMID: 11730945
27. Frisullo G, Nociti V, Iorio R, Katia Patanella A, Bianco A, et al. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol. 2007; 124: 284-293. PMID: 17627892
28. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990; 113:1477-1489. PMID: 2245307
29. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res. 2009; 2:1-19. PMID: 22084578
30. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2, 3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem. 1994; 269:14457-14464. PMID: 7514170
31. Terentis AC, Thomas SR, Takikawa O, Littlejohn TK, Truscott RJ, Armstrong RS, et al. The heme environment of recombinant human indoleamine 2, 3-dioxygenase. Structural properties and substrate-ligand interactions. J Biol Chem. 2002; 277:15788-15794. PMID: 11867636
32. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999; 189:1363-1372. PMID: 10224276
33. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes acti-vatedTcells toapoptosis priortocell division. Immunology. 2002; 107:452-460. PMID: 12460190
34. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, et al. IDO activates regulatory T cells and blocks their conversion into Th17-likeT cells. J Immunol. 2009; 183: 2475-2483. doi: 10. 4049/jimmunol.0900986 PMID: 19635913
35. Saresella M, Marventano I, Longhi R, Lissoni F, Trabattoni D, Mendozzi L, et al. CD4+CD25+FoxP3 +PD1-regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008; 22: 3500-3508. doi: 10.1096/fj.08-110650 PMID: 18587005
36. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008; 123: 79-89. PMID: 17897326